Similarly, in a population-based cohort study of more than 200,000 patients, there was no difference in the risk of UTI events between patients initiating SGLT2 inhibitors compared to those initiating DPP-4 inhibitors or GLP1 RA treatment (79). The gene discussed is DPP4; the disease is bacterial urinary tract infection.